MEOW-1 Trial Starts: What to Know About 'Cat Ozempic'
Summary
OKAVA Pharmaceuticals has begun a clinical trial called MEOW-1 to test a weight loss treatment for obese cats using a GLP-1 implant. This trial involves up to 50 cats and aims to explore new ways to manage cat obesity, diabetes, and kidney disease with a long-lasting implant.Key Facts
- OKAVA Pharmaceuticals started a clinical trial named MEOW-1 for their product OKV-119, a GLP-1 implant for cats.
- The trial involves up to 50 cats and monitors their weight and health at three and six months.
- OKV-119 uses a technology called NanoPortal™ for a steady and long-lasting release of exenatide, a drug used in human diabetes treatments.
- The GLP-1 implant helps cats feel full, slow digestion, and manages blood sugar levels.
- The implant provides up to six months of treatment with one administration, unlike frequent injections.
- The trial is listed with the American Veterinary Medical Association Clinical Trials Registry.
- Results from the study are expected in summer 2026, and if successful, a similar trial in dogs is planned.
- OKAVA seeks FDA approval for OKV-119 between 2027 and 2028, with the cost possibly around $100 per month for pet owners.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.